About Kairos Therapeutics
Kairos Therapeutics is a company based in Vancouver (Canada) founded in 2013 was acquired by Zymeworks in March 2016. Kairos Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, MiRagen, Avidity Biosciences and Ikena Oncology, among others.
- Headquarter Vancouver, Canada
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Kairos Therapeutics
Detailed funding history for Kairos Therapeutics
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Kairos Therapeutics
Kairos Therapeutics has secured backing from 1 investor. Prominent investors backing the company include Zymeworks.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Bi-specific antibodies and antibody-drug conjugates are developed for cancer treatment.
|
Locked | Locked | Locked |
Investor details for Kairos Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kairos Therapeutics
Investment portfolio details for Kairos Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Kairos Therapeutics
Detailed financials for Kairos Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kairos Therapeutics Comparisons
Peer comparison for Kairos Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Kairos Therapeutics
Kairos Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, MiRagen, Avidity Biosciences and Ikena Oncology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Developer of biomarker-based therapies for treating cancer
|
|
| Locked | Locked | Locked |
Small molecule protein degraders are developed for various disorders.
|
Detailed competitors of Kairos Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kairos Therapeutics
Complete news archive for Kairos Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kairos Therapeutics
Kairos Therapeutics was founded in 2013.
Kairos Therapeutics is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
Kairos Therapeutics was founded in 2013 in Vancouver, Canada, as a biopharmaceutical company. A proprietary next-generation antibody-drug conjugate platform is utilized, incorporating novel toxin, linker, and site-specific conjugation technologies. This approach supports the creation of targeted cancer therapeutics with minimized side effects. A pipeline of antibody-drug conjugates for various cancers is advanced through partnerships. The company was acquired by Zymeworks in March 2016.
Kairos Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Kairos Therapeutics has 1 investor. Key investors include Zymeworks.